By a recent decision, the Delhi High Court seems to have put a long drawn battle between US incorporated Pharma giant Bristol-Myers Squibb (BMS) and Mumbai based Indian Drug Company BDR Pharma (previously MJ Chempharma Private Limited) over anti-cancer drug Dasatinib to a temporary halt. By this decision the High Court prima facie upheld the validity of the BMS’ patent (IN 203937) for the said drug and maintained the order of interim injunction against BDR Pharma. The genesis of the entire![]()
